Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Fineline Cube Jan 13, 2026
Company Deals

HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases

Fineline Cube Dec 20, 2024

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine

Fineline Cube Dec 20, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...

Company Deals

Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment

Fineline Cube Dec 20, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial

Fineline Cube Dec 20, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...

Company Drug

MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review

Fineline Cube Dec 19, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company Deals

Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases

Fineline Cube Dec 19, 2024

US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE:...

Company Deals

Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development

Fineline Cube Dec 19, 2024

Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids...

Company Deals

BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets

Fineline Cube Dec 19, 2024

US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...

Company Medical Device

DaAn Gene Co., Ltd Receives NMPA Approval for Genetic Deafness Gene Detection Kit

Fineline Cube Dec 19, 2024

China-based DaAn Gene Co., Ltd, (SHE: 002030) affiliated with Sun Yat-sen University, has announced that...

Company Drug

MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer

Fineline Cube Dec 19, 2024

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced that the US Food and...

Company Deals

BMS Regains Exclusive Rights to ABZ-706 in Greater China

Fineline Cube Dec 19, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...

Company Drug

Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults

Fineline Cube Dec 19, 2024

China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...

Company Drug

FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients

Fineline Cube Dec 19, 2024

On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical...

Company Deals

INT Medical Instruments to Acquire Controlling Stake in Weiqiang Medical Technology for RMB 230 Million

Fineline Cube Dec 19, 2024

Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) has announced its intention to acquire at...

Company Drug

Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma

Fineline Cube Dec 19, 2024

Janssen-Cilag International NV has announced the submission seeking approval for an indication extension of IMBRUVICA...

Company Deals

iFlytek’s Subsidiary Xunfei Healthcare Technologies Lists on HKEX, Raises Over HKD 580 Million

Fineline Cube Dec 19, 2024

Xunfei Healthcare Technology Co., Ltd, a subsidiary of China-based information technology company iFlytek Co., Ltd...

Company Drug

Chengdu Kanghua Biological Receives NMPA Approval for Recombinant Norovirus Vaccine

Fineline Cube Dec 19, 2024

Chengdu Kanghua Biological Products Co., Ltd, (SHE: 300841), a leading biopharmaceutical company based in China,...

Company Medical Device

Sinocare Inc’s TRUE VIE CGMS Advances to 510(k) Substantive Review Stage at FDA

Fineline Cube Dec 19, 2024

Sinocare Inc (SHE: 300298), a China-based medical technology company, has announced that its continuous glucose...

Company Drug

Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial

Fineline Cube Dec 19, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1501 Combo in Bladder Cancer

Fineline Cube Dec 19, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Posts pagination

1 … 185 186 187 … 609

Recent updates

  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
  • Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
  • ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.